Allen Mooney & Barnes Investment Advisors LLC Purchases New Holdings in Becton, Dickinson and Company $BDX

Key Points

• Allen Mooney & Barnes Investment Advisors acquired 106,244 Becton, Dickinson and Company shares worth approximately $16.1 million, making BDX 2.4% of its portfolio. Institutional investors collectively own 86.97% of the company.
• Analyst sentiment is mixed, with eight Buy, eight Hold and one Sell rating; the consensus is Hold with a $187.67 price target. BDX recently traded at $187.54, near its 52-week high.
• Becton, Dickinson exceeded quarterly earnings and revenue expectations, reporting $3.23 EPS and $4.98 billion in revenue, while maintaining fiscal 2026 EPS guidance of $12.62–$12.72. The company also declared a $1.05 quarterly dividend, equivalent to a 2.2% annualized yield.

Allen Mooney & Barnes Investment Advisors LLC acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 106,244 shares of the medical instruments supplier's stock, valued at approximately $16,078,000. Becton, Dickinson and Company makes up 2.4% of Allen Mooney & Barnes Investment Advisors LLC's holdings, making the stock its 16th biggest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth $25,000. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at about $26,000. Meeder Asset Management Inc. boosted its holdings in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 102 shares during the last quarter. Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $29,000. Finally, Bell Investment Advisors Inc bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $29,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BDX shares. Royal Bank Of Canada increased their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Jefferies Financial Group reiterated a "buy" rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Bank of America lifted their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $187.67.

Becton, Dickinson and Company Stock Up 0.0%

Becton, Dickinson and Company stock opened at $187.54 on Friday. The company has a 50 day moving average of $169.48 and a 200-day moving average of $160.52. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $193.07. The stock has a market capitalization of $51.67 billion, a PE ratio of 56.49, a price-to-earnings-growth ratio of 13.22 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company's revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,105 shares of company stock worth $1,590,208 in the last three months. 0.40% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source